tembotrione

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Kašuba, Vilena: 1 article (08/2016)
2.	Kopjar, Nevenka: 1 article (08/2016)
3.	Marjanović, Ana Marija: 1 article (08/2016)
4.	Milić, Mirta: 1 article (08/2016)
5.	Pavičić, Ivan: 1 article (08/2016)
6.	Pizent, Alica: 1 article (08/2016)
7.	Rozgaj, Ružica: 1 article (08/2016)
8.	Tariba, Blanka: 1 article (08/2016)
9.	Vrdoljak, Ana Lucić: 1 article (08/2016)
10.	Želježić, Davor: 1 article (08/2016)

1.	Hepatocellular Carcinoma (Hepatoma) 08/01/2016 - "This study evaluated the impact of acute (4 and 24 h) exposure to low concentrations of tembotrione [corresponding to the acceptable daily intake (0.17 μg/mL), residential exposure level (0.002 μg/mL) and acceptable operator exposure level (0.0012 μg/mL)] on human hepatocellular carcinoma cell line HepG2, using biomarkers of oxidative stress, CCK-8 colorimetric assay for cell viability, alkaline comet assay, and cytokinesis-block micronucleus "cytome" assay. "
2.	Chromosome Aberrations (Chromosome Abnormalities) 08/01/2016 - "Regardless of the fact that tembotrione was previously reported negative for mutations and chromosome aberrations in vitro, our findings call for more precaution in its use. "

1.	Biomarkers (Surrogate Marker)
2.	Sincalide